04:22 AM EDT, 05/06/2024 (MT Newswires) -- Cellectis ( CLLS ) said Monday that AstraZeneca ( AZN ) has completed an additional equity investment of $140 million in the company, after clearance from the French Ministry of Economy.

AstraZeneca ( AZN ) has subscribed for 10 million class A convertible preferred shares and 18 million class B convertible preferred shares priced at $5 per convertible preferred share of Cellectis ( CLLS ).

Following the additional investment, AstraZeneca ( AZN ) owns about 44% of the share capital and 30% of the voting rights of the company.

Price: 2.9300, Change: -0.06, Percent Change: -2.01